| Haiyitan (gumarontinib) / HaiHe Biopharma |
ChiCTR2400080439: Efficacy and Safety of Glumetinib in patients with MET alteration NSCLC: a Multicenter, observational Real World Study based on digital follow-up |
|
|
| Recruiting | 4 | 200 | | Observational study, not applicable; Observational study, not applicable; Observational study, not applicable | Beijing Cancer Hospital; Beijing Cancer Hospital, CSPC Ouyi Pharmaceutical Co., Ltd. | Non-small cell lung cancer | | | | |
ChiCTR2400080739: An exploratory multi-cohort Clinical Study of Glumetinib in the treatment of advanced non-small cell lung cancer brain metastases with MET alterations (BRAIN-MET01) |
|
|
| Recruiting | 4 | 40 | | Glumetinib (300mg) will be administered orally in a 4-week treatment cycle, once a day from day 1 to day 28 of each cycle.; Glumetinib+FurmonertinibGlumetinib (300mg) will be administered orally in a 4-week treatment cycle, once a day from day 1 to day 28 of each cycle.Furmonertinib (80mg) will be administered orally in a 4-week treatment cycle, once a day from day 1 to day 28 of each cycle. | Beijing Tiantan Hospital, Capital Medical University; Beijing Tiantan Hospital, Capital Medical University, CSPC Ouyi Pharmaceutical Co., Ltd. | NSCLC | | | | |
NCT06452433: Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer. |
|
|
| Not yet recruiting | 2 | 91 | NA | gumarontinib, SCC244, third-generation EGFR-TKI (Osimertinib, Almonertinib or Furmonertinib), third-generation EGFR-TKI | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Non-small Cell Lung Cancer | 12/27 | 02/28 | | |
NCT06525350: A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel（Albumin Bound）Verse Docetaxel for the Treatment of MET-overexpressed Non-small Cell Lung Cancer |
|
|
| Not yet recruiting | 2 | 256 | NA | Glumetinib tablets, HB1801 (docetaxel, albumin-bound）, Docetaxel | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Locally Advanced/Recurrent or Distant Metastasized Non-small Cell Lung Cancer With MET Overexpression | 12/26 | 06/28 | | |
CT32, NCT04797702: Glumetinib Combined With Toripalimab in the Treatment of Relapsed or Metastatic Non-small Cell Lung Cancer. |
|
|
| Recruiting | 1/2 | 67 | RoW | Glumetinib combined with Toripalimab | Shanghai Junshi Bioscience Co., Ltd. | Relapsed or Metastatic Non-small Cell Lung Cancer | 07/23 | 02/24 | | |
GLORY, NCT04270591: Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 183 | Japan, US, RoW | Glumetinib, SCC244 | Haihe Biopharma Co., Ltd. | C-Met Exon 14 Mutation | 10/23 | 12/23 | | |
